一项针对新诊断的免疫性血小板减少性紫癜患者使用硼替佐米、环磷酰胺和地塞米松的2期前瞻性研究。（注：原文中iMCD可能有误，推测为ITP即免疫性血小板减少性紫癜，若不是该病症请根据准确信息修改译文） - Suppr | 超能文献

相似文献

1

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD.一项针对新诊断的免疫性血小板减少性紫癜患者使用硼替佐米、环磷酰胺和地塞米松的2期前瞻性研究。（注：原文中iMCD可能有误，推测为ITP即免疫性血小板减少性紫癜，若不是该病症请根据准确信息修改译文）

Blood. 2023 May 25;141(21):2654-2657. doi: 10.1182/blood.2023020009.

2

Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.每周环磷酰胺-硼替佐米-地塞米松方案作为新诊断多发性骨髓瘤日本患者自体干细胞移植前诱导治疗的疗效和安全性：一项 2 期多中心试验。

Acta Haematol. 2019;141(2):111-118. doi: 10.1159/000495338. Epub 2019 Feb 6.

3

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.环磷酰胺、硼替佐米与地塞米松适应性强化治疗对比未强化治疗用于新诊断的多发性骨髓瘤患者（骨髓瘤XI）：一项多中心、开放标签、随机、3期试验

Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.

4

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.环磷酰胺、硼替佐米与地塞米松诱导治疗新诊断多发性骨髓瘤患者的长期生存情况

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30.

5

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.剂量降低的硼替佐米、环磷酰胺和地塞米松（“VCD-Lite”）用于新诊断的老年或其他对毒性敏感的成年多发性骨髓瘤患者的II期研究。

J Geriatr Oncol. 2017 May;8(3):165-169. doi: 10.1016/j.jgo.2017.02.004. Epub 2017 Feb 28.

6

A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.一项关于硼替佐米、环磷酰胺和地塞米松用于复发/难治性免疫性疾病相关的多中心前瞻性研究。（这里“iMCD”推测为免疫性疾病相关，原文未明确全称，具体翻译可根据实际全称调整）

Leuk Lymphoma. 2022 Mar;63(3):618-626. doi: 10.1080/10428194.2021.1999437. Epub 2022 Jan 31.

7

A new standard of care in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤的一种新护理标准。

Lancet. 2010 Dec 18;376(9758):2043-4. doi: 10.1016/S0140-6736(10)62177-0. Epub 2010 Dec 9.

8

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.一项关于环磷酰胺、硼替佐米、聚乙二醇化脂质体阿霉素和地塞米松用于新诊断骨髓瘤的开放标签I/II期研究。

Eur J Haematol. 2015 Nov;95(5):426-35. doi: 10.1111/ejh.12509. Epub 2015 Mar 12.

9

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.DSMM XI研究：静脉注射环磷酰胺联合硼替佐米/地塞米松用于新诊断骨髓瘤患者诱导缓解的剂量定义

Ann Hematol. 2009 Nov;88(11):1125-30. doi: 10.1007/s00277-009-0726-6. Epub 2009 Mar 10.

10

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.在新诊断的多发性骨髓瘤中，硼替佐米与环磷酰胺、硼替佐米和地塞米松（CyBorD）联合使用时，每周一次与每周两次诱导治疗的对比

Blood. 2010 Apr 22;115(16):3416-7. doi: 10.1182/blood-2010-02-271676.

引用本文的文献

1

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.中国iMCD患者使用司妥昔单抗的真实世界数据：联合BCD方案作为重症病例的潜在治疗方法

Ann Hematol. 2025 Mar;104(3):1713-1720. doi: 10.1007/s00277-025-06329-7. Epub 2025 Apr 3.

2

Spontaneous remission of iMCD-TAFRO: a case report.iMCD-TAFRO综合征的自发缓解：一例报告

Ann Hematol. 2025 Apr;104(4):2559-2561. doi: 10.1007/s00277-025-06324-y. Epub 2025 Mar 26.

3

[The guidelines for the diagnosis and treatment of Castleman disease in China (2025)].